Campbell & CO Investment Adviser LLC Takes $1.19 Million Position in Novavax, Inc. $NVAX

Campbell & CO Investment Adviser LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 189,426 shares of the biopharmaceutical company’s stock, valued at approximately $1,193,000. Campbell & CO Investment Adviser LLC owned approximately 0.12% of Novavax as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of NVAX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 2,750 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Novavax by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,169 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 2,780 shares in the last quarter. Signaturefd LLC lifted its position in shares of Novavax by 47.2% in the second quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 3,122 shares in the last quarter. Monaco Asset Management SAM boosted its holdings in Novavax by 1.8% during the first quarter. Monaco Asset Management SAM now owns 290,000 shares of the biopharmaceutical company’s stock worth $1,859,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Novavax by 11.1% in the first quarter. Federated Hermes Inc. now owns 56,124 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 5,618 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Bank of America reaffirmed an “underperform” rating and issued a $7.00 target price (down previously from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research report on Wednesday, October 8th. HC Wainwright raised their price target on Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, TD Cowen dropped their price objective on Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.38.

Novavax Stock Performance

NVAX opened at $7.20 on Thursday. The company has a quick ratio of 2.34, a current ratio of 2.36 and a debt-to-equity ratio of 5.93. Novavax, Inc. has a 12-month low of $5.01 and a 12-month high of $11.55. The business has a 50 day moving average of $8.38 and a 200-day moving average of $7.58. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 3.16, a PEG ratio of 0.12 and a beta of 2.69.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business had revenue of $70.45 million during the quarter, compared to the consensus estimate of $55.63 million. During the same quarter last year, the company posted ($0.76) EPS. The firm’s revenue was down 16.7% on a year-over-year basis. Novavax has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.